UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 96

Sortiert nach

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

Future oncology (London, England), 2018-03, Vol.14 (6), p.499-513

2018

Link zum Volltext

Verfügbarkeit prüfen

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant

European journal of haematology, 2022-10, Vol.109 (4), p.364-372

2022

Link zum Volltext

Verfügbarkeit prüfen

The Treatment of Chronic Lymphatic Leukemia

Deutsches Ärzteblatt international, 2019-01

2019

Link zum Volltext

Verfügbarkeit prüfen

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

Leukemia, 2019-05, Vol.33 (5), p.1161-1172

2019

Link zum Volltext

Verfügbarkeit prüfen

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations

American journal of hematology, 2024-08, Vol.99 (8), p.1620-1623

2024

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial

American journal of hematology, 2024-06, Vol.99 (6), p.1192-1195

2024

Link zum Volltext

Verfügbarkeit prüfen

The Treatment of Chronic Lymphatic Leukemia

Deutsches Ärzteblatt international, 2019-01, Vol.116 (4), p.41-46

2019

Link zum Volltext

Verfügbarkeit prüfen

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia

American journal of hematology, 2021-12, Vol.96 (12), p.E457-E460

2021

Link zum Volltext

Verfügbarkeit prüfen

MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics

Scientific reports, 2023-03, Vol.13 (1), p.4792-4792, Article 4792

2023

Link zum Volltext

Verfügbarkeit prüfen

Cannabinoids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases

Cellular & molecular immunology, 2021-03, Vol.18 (3), p.764-766

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia

British journal of haematology, 2018-12, Vol.183 (5), p.727-735

2018

Link zum Volltext

Verfügbarkeit prüfen

Thymic hyperplasia after mRNA based Covid-19 vaccination

Radiology case reports, 2021-12, Vol.16 (12), p.3744-3745

2021

Link zum Volltext

Verfügbarkeit prüfen

Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma

European journal of haematology, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(96)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(55)
Humans
(40)
Hematology
(33)
Oncology
(29)
Female
(25)
Male
(24)
Middle Aged
(23)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Adult
(18)
Aged
(16)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(16)
Chronic Lymphocytic Leukemia
(15)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(13)
Lymphoma
(13)
Leukemia
(12)
Patients
(12)
Prognosis
(10)
Chemotherapy
(9)
Immunotherapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant

The Treatment of Chronic Lymphatic Leukemia

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial

The Treatment of Chronic Lymphatic Leukemia

Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia

MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics

Cannabinoids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia

Long‐term follow‐up and health‐related quality of life among cancer survivors with stage IEA orbital‐type lymphoma after external photon‐beam radiotherapy: Results from a longitudinal study

Thymic hyperplasia after mRNA based Covid-19 vaccination

Long-Term Follow-Up of Patients with Conjunctival Lymphoma after Individualized Lens-Sparing Electron Radiotherapy: Results from a Longitudinal Study

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME‐LIMITED TREATMENT WITH ANTI‐CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2‐BAG, ‐BCG, ‐BIG AND ‐BIO PHASE‐II TRIALS

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ‐ INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE‐II CLL‐FRAIL TRIAL

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

Suchergebnisse filtern